Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

January 11, 2025

Study Completion Date

January 20, 2026

Conditions

Hypertension,Essential

Interventions

DRUG

SGB-3908

SGB-3908 for sc injection

OTHER

SGB-3908-Matching placebo

Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered

Trial Locations (1)

Peking University Third Hospital, Beijing

All Listed Sponsors

collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Suzhou Sanegene Bio Inc.

INDUSTRY

NCT06501586 - Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects | Biotech Hunter | Biotech Hunter